Wiskott-Aldrich syndrome
- 1 January 2008
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Current Opinion in Hematology
- Vol. 15 (1), 30-36
- https://doi.org/10.1097/moh.0b013e3282f30448
Abstract
Wiskott-Aldrich syndrome is caused by mutations of the Wiskott-Aldrich syndrome protein gene, which codes for a cytoplasmic protein with multiple functions. This review will focus on recent progress in understanding the molecular basis of Wiskott-Aldrich syndrome and its ramifications for the cure of this lethal disease. The discovery of the causative gene has revealed a spectrum of clinical phenotypes demonstrating a strong genotype/phenotype correlation. The discovery of unique functional domains of Wiskott-Aldrich syndrome protein has been instrumental in defining mechanisms that control activation of Wiskott-Aldrich syndrome protein. Long-term follow up of patients undergoing hematopoietic stem cell transplantation has led to important modifications of the procedure. Studies of Wiskott-Aldrich syndrome protein-deficient cell lines and wasp-knockout mice have paved the way for possible gene therapy. Wiskott-Aldrich syndrome protein gene mutations result in four clinical phenotypes: classic Wiskott-Aldrich syndrome and X-linked thrombocytopenia, intermittent thrombocytopenia and neutropenia. Wiskott-Aldrich syndrome protein is a signaling molecule and instrumental for cognate and innate immunity, cell motility and protection against autoimmune disease. The success of hematopoietic stem cell transplantation is related to the recipient's age, donor selection, the conditioning regimen and the extent of reconstitution. Since Wiskott-Aldrich syndrome protein is expressed exclusively in hematopoietic stem cells, and because Wiskott-Aldrich syndrome protein exerts a strong selective pressure, gene therapy is expected to cure the disease.Keywords
This publication has 60 references indexed in Scilit:
- Successful treatment of lymphoproliferative disease complicating primary immunodeficiency/immunodysregulatory disorders with reduced-intensity allogeneic stem-cell transplantationBlood, 2007
- Unregulated actin polymerization by WASp causes defects of mitosis and cytokinesis in X-linked neutropeniaThe Journal of Experimental Medicine, 2007
- Wiskott-Aldrich syndrome protein is required for regulatory T cell homeostasisJCI Insight, 2007
- Stem cell transplantation for the Wiskott–Aldrich syndrome: a single-center experience confirms efficacy of matched unrelated donor transplantationBone Marrow Transplantation, 2006
- Mosaicism of NK cells in a patient with Wiskott-Aldrich syndromeBlood, 2005
- Stem cell transplantation for congenital immunodeficiencies using reduced-intensity conditioningBone Marrow Transplantation, 2005
- A conserved amphipathic helix in WASP/Scar proteins is essential for activation of Arp2/3 complexNature Structural & Molecular Biology, 2003
- Gene therapy for Wiskott-Aldrich syndrome: rescue of T-cell signaling and amelioration of colitis upon transplantation of retrovirally transduced hematopoietic stem cells in miceBlood, 2002
- Phosphorylation of Tyrosine 291 Enhances the Ability of WASp to Stimulate Actin Polymerization and Filopodium FormationPublished by Elsevier BV ,2002
- A multiinstitutional survey of the Wiskott-Aldrich syndromeThe Journal of Pediatrics, 1994